The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Soft tissue sarcomas (STS) are a group of uncommon neoplasms that are difficult to treat when unresectable. We present our initial data on Y-90 radioembolization (RE) of STS, both primary and metastatic to the liver.Between November 2006 and June 2012, 11 patients with primary and metastatic STS involving the liver underwent 12 Y-90 RE treatments. Nine of 11 (81.8%) patients had prior unsuccessful...
Thrombocytopenia is often observed after Yttrium-90 hepatic radioembolization (RE). Mechanisms may include direct radiation toxicity in the blood compartment, marrow suppression, or sequestration. We sought to identify the causative factors by retrospective analysis.All patients with complete baseline and 3 month post-RE imaging and lab data were included in the analysis. Uni- and multivariate regression...
Yttrium-90 radioembolization (RE) treatment of hepatocellular carcinoma (HCC) may be performed with either resin or glass microspheres. Differences include specific activity, microsphere size and density, embolic effect, and dose calculation. We retrospectively reviewed the differences in outcome between patients treated with glass microspheres and patients treated with resin microspheres prior to...
Yttrium-90 (90Y) radioembolization dose planning requires balancing caution against toxicity with aggressiveness for efficacy, but each is impossible to predict based solely on morphologic imaging. We investigate the use of fusion MAA-sulfur colloid SPECT imaging to provide physiologic information relevant to dose calculation and outcomes.A dual SPECT protocol was used with IA injection of technetium-99m...
Consensus guidelines dictate that patients with high hepatopulmonary shunt fractions should not undergo Y-90 radioembolization (RE), or should have administered activity reduced 20-40% to decrease the risk of radiation pneumonitis. We reviewed our experience of managing and treating patients with high shunt fractions.We retrospectively reviewed 247 patients treated from 2004-11. We calculated pulmonary...
Standard of care formulae for dose calculation for yttrium-90 hepatic radioembolization (RE) result in a wide range of efficacy and toxicity. A retrospective analysis was performed on patients treated with resin microspheres to calculate actual absorbed dose and to correlate this with clinical toxicity and response.All 247 patients treated with RE at a single center were retrospectively reviewed,...